Asarina Pharma AB (publ) Interim Report Q2 2019 released
Asarina Pharma CEO Peter Nordkild: “This has been a Quarter of important milestones: last patient in for our Phase IIb PMDD study, FDA approval of our IND for Sepranolone, Clinical Trial Approval for our Phase IIa Menstrual Migraine study and growing interest from future potential partners.”FINANCIAL HIGHLIGHTS 1 April – 30 June 2019 TOTAL OPERATING COSTS SEK 28.1M (11.5M) NET RESULT -25.8M (-9.7M) CASH AND CASH EQUIVALENTS (30 JUNE 2019): SEK 109.5M (9.7M) SIGNIFICANT EVENTS DURING THE SECOND QUARTER WHO classification of PMDD In May PMDD (Premenstrual Dysphoric Disorder)